•  
  •  
 

Central Asian Journal of Medicine

Abstract

Despite adequate hypolipidemic therapy, the risk of cardiovascular complications remains high. This review provides a scientific overview of current LDL receptor data, the importance of PCSK9 in receptor-level regulation, and the influence of lipoprotein (a) and the role of lipoprotein-associated phospholipase A2 in the development and progression of atherosclerosis. LDL receptors play a crucial role in the exchange of cholesterol LDL in the body. It has been shown that PCSK9 is involved in the destruction of LDL receptors, being the primary regulator of its expression on the cell surface. There is strong evidence of association between a continuous and independent high-level Lp (a) and increased risk of CVD development and progression of atherosclerosis in various vascular structures.

First Page

5

Last Page

19

References

1. Gyerasimov A. M., Chyerkavskaya O. V., Maslennikov M. A., Kochetov A. Kletochnie mehanizmi, klinicheskie i morfo- logicheskie faktori riska razvitiya restenoza. Vestn. rentgenol. radiol. 2011;4:58–65. 2. Diagnostika i korrekciya narusheniy lipidnogo obmena s cel'yu profilaktiki i lecheniya atyerosklyeroza. Rossiyskie rekomendacii V pyeresmotr / M. V. Ejov, I. V. Syergienko, V. V. Kuharchuk [i dr.]; Rossiyskoe kardiologicheskoe obshhestvo [i dr.]. – Tekst : elektronniy // Atyerosklyeroz i diclipidemii.2012.-4.S.4–52. 3. Ejov M. V., Safarova M. S., Afanas'yeva O. I., Il'ina L. N., Lyakishev A. A., Pokrovskiy S. N. Lipoprotein (a) kak prediktor neblagopriyatnogo prognoza v otdalennie sroki posle opyeracii koronarnogo shuntirovaniya. Kardiologiya. 2011;51(1):18–22. [ 4. Ejov M. V., Safarova M. S., Mal'chin Yu. G., Sobolyeva D. I., Afanas'yeva O. I., Pokrovskiy S. N. Svyaz' visokogo urovnya lipoproteina (a) s prohodimost'yu koronarnih artyeriy v techenie pyervogo goda posle chreskojnih koronarnih vmeshatel'stv. Klinicist. 2011;1:18–24. 5. Kuharchuk V.V., Malishev P.P., Meshkov A.N. Semeynaya gipyerholestyerinemiya: sovremennie aspekti diagnostiki, profilaktiki i tyerapii // Kardiologiya. 2009. - 49. S. 76–84. 6. Osipenko, A. N. Jirnie kisloti krovi i ih vzaimosvyazi pri atyerosklyeroze / A. N. Osipenko, N. V. Akulich, F. N. Klishevich // Tavricheskiy mediko-biologicheskiy vestnik. – 2012. – T. 15, - 3. – S. 197–199. 7. Spravochnik Vidal'. Lekarstvennie preparati v Rossii. – M., AstraFarmSyervis, 2011. – 1728 s. 8. Statini v sovremennoy kardiologicheskoy praktike / Yu. N. Belenkov, I. V. Syergienko, A. A. Lyakishev, V. V. Kuharchuk – M., 2010. – 64 c. 9. Statini, fibrati i venoznaya tromboemboliya: metaanaliz / A. Skvizzato, M. Galli, E. Romualdi i dr. // Syercyeva nedostatnist'. – 2011. – - 2. – S. 107–116. 10. Central'niy NII organizacii i informatizacii zdravoohraneniya [Elektronniy resurs] / Ministyerstvo zdravoohraneniya Rossiyskoy Fedyeracii. – Elektron. dan. – Rejim dostupa : http://zo.mednet.ru/bd_zo_rf/zo_rf.php?type=1. – Zagl. s ekr 11. Shal'nova S.A., Deev A.D. Haraktyeristika pacientov visokogo riska. Rezul'tati epidemiologicheskoy chasti nauchno-obrazovatel'noy programmi OSKAR. // Kardiovask. tyerapiya i profilakt. – 2006. – T.5(5). – S. 59-61Almontashiri N. A., Vilmundarson R. O., Ghasemzadeh N., Dandona S., Roberts R., Quyyumi A. A., Chen H. H., Stewart A. F. PLoS One. 2014, vol. 9 (9), p. e106294.Cariou B., Guerin P., Le May C., Letocart V., Arnaud L., Guyomarch B., Pichelin M., Probst V. Diabetes Metab. 2017, vol. 43 (6), pp. 529‒535. 12. Anping Cai, Liwen Li, Zhang Y. Lipoprotein (a): a promising marker for residual cardiovascular risk assessment. Dis Markers. 2013;35(5):551–559. 13. Association between the lipoprotein‐associated phospholipase A2 activity and the progression of subclinical atherosclerosis / J. Liu, W. Wang, Y. Qi [et al.]. – Text : electronic // J. Atheroscler. Thromb. – 2014. – Vol. 21, № 6. – P. 532–542. – URL: https://www.ncbi.nlm.nih.gov/pubmed/24492522 (date of the application: 17.09.2019). 14. Association of lipoprotein-associated phospholipase A2 levels with coronary artery disease and major adverse events at follow-up / E. S. Brilakis, J. P. McConnell, R. J. Lennon [et al.]. – Text : electronic // Eur. Heart J. – 2005. – Vol. 26, № 2. – P. 137–144. – URL:ttps://www.ncbi.nlm.nih.gov/pubmed/15618069. (date of the application: 22.10.2019). 15. Association of lipoprotein-associated phospholipase A2 mass and activity with calcified coronary plaque in young adults: the CARDIA study / C. Iribarren, M. D. Gross, J. A. Darbinian [et al.] // Arterioscl. Thromb. Vasc. Biol. – 2005. – Vol. 25, № 1. – P. 216–221. – DOI: 10.1161/01.ATV.0000148322.89911.44. 16. Bays, H. Statin safety: an overview and assessment of the data 2005 / H. Bays // Am. J. Cardiol. – 2006. – Vol. 97. – Р. 6–27. 17. Changes in lipoprotein‐associated phospholipase A2 activity predict coronary events and partly account for the treatment effect of pravastatin: results from the Long‐Term Intervention with Pravastatin in Ischemic Disease study / H. D. White, J. Simes, R. A. Stewart [et al.] // J. Am. Heart Assoc. – 2013. – Vol. 2, № 5. – P. e000360. – DOI: 10.1161/JAHA.113.000360. 18. Cheng J. M., Oemrawsingh R. M., Garcia-Garcia H. M., Boersma E., van Geuns R. J., Serruys P. W., Kardys I., Akkerhuis K. M. Atherosclerosis. 2016, vol. 248, pp. 117‒122. 19. C‐reactive protein and lipoprotein‐associated phospholipase A2 in smokers and nonsmokers of the Ludwigshafen Risk and Cardiovascular Health study /M. E. Kleber, R. Siekmeier, G. Delgado [et al.] // Adv. Exp. Med. Biol. – 2015. – Vol. 832. – P. 15–23. – DOI: 10.1007/5584_2014_6. 20. Ding Z., Liu S., Wang X., Deng X., Fan Y., Shahanawaz J., Shmookler Reis R. J., Varughese K. I., Sawamura T., Mehta J. L. Cardiovasc. Res. 2015, vol. 107 (4),pp. 556‒567. Commun. 2013,vol. 440 (2), pp. 210‒214. 21. Discovery of a new class of HMG-CoA reductase inhibitor from Polyalthia longifolia as potential lipid lowering agent / K. V. Sashidhara, S. P. Singh, Srivastava et al. // Eur J Med Chem. – 2011. – Vol. 46, № 10. – P. 5206–5211. 22. Dwivedi D. J., Grin P. M., Khan M., Prat A., Zhou J., Fox-Robichaud A. E., Seidah N. G., Liaw P. C. Shock. 2016, vol. 46 (6), pp. 672‒680. 23. Enhanced expression of Lp-PLA2 and lysophosphatidylcholine in symptomatic carotid atherosclerotic plaques / D. Mannheim, J. Herrmann, D. Versari [et al.]//Stroke. –2008.–Vol. 39, № 5. – P. 1448–1455.–DOI: 10.1161/Strokeaha.107.503193. 24. Ezhov MV, Safarova MS, Afanasieva OI, Kukharchuk VV, Pokrovsky SN. Lipoprotein (a) level and apolipoprotein (a) phenotype as predictors of long-term cardiovascular outcomes after coronary artery bypass grafting. Atherosclerosis. 2014;235 (2):477–482. 25. Ezov MV, Afanasieva OI, Adamova L. Lipoprotein (a) levels predict myocardial infarction in yang men. Atherosclerosis. 2000;51(1):304. 26. Ferri N., Tibolla G., Pirillo A., Cipollone F., Mezzetti A., Pacia S., Corsini A., Catapano A. L. Atherosclerosis. 2012, vol. 220 (2), pp. 381‒386. 27. Fruchart JC, Sacks FM, Hermans MP. The residual risk reduction initiative: a call to action to reduce residual risk in dyslipideamic patients. Diab Vasc Dis Res. 2010;2:319-335. 28. Gencer B., Montecucco F., Nanchen D., Carbone F., Klingenberg R., Vuilleumier N., Aghlmandi S., Heg D., Raber L., Auer R., Juni P., Windecker S., Luscher T. F., Matter C. M., Rodondi N., Mach F. European Heart Journal. 2016, vol. 37 (6), pp. 546‒553. 29. Goldstein J.L., Brown M.S. The LDL receptor // Arterioscler. Thromb. Vasc. Biol. 2009. Vol. 29. P. 431–438. 30. Graham MJ, Viney N, Crooke RM, Tsimikas S. Antisense inhibition of apolipoprotein (a) to lower plasma lipoprotein (a) levels in humans. J Lipid Res. 2016;57(3):340–351. 31. Holmes DT, Schick BA, Humphries KH, Frohlich J. Lipoprotein (a) is an independent risk factor for cardiovascular disease in heterozygous familial hypercholesterolemia. Clin Chem. 2005;51(11):2067–2073. 32. Interpretation of lipoprotein-associated phospholipase A2 levels is influenced by cardiac disease, comorbidities, extension of atherosclerosis and treatments / J. C. Charniot, R. Khani-Bittar, J. P. Albertini [et al.] // Int. J. Cardiol. – 2013. – Vol. 168, № 1. – P. 132–138. – DOI: 10.1016/j.ijcard.2012.09.054. 33. Jansen AC, van Aalst-Cohen ES, Tanck MW, Trip MD, Lansberg PJ, Liem AH et al. The contribution of classical risk factors to cardiovascular disease in familial hypercholesterolaemia: data in 2400 patients. J Intern Med. 2004;256(6):482–490. 34. Jayasinghe R, Craig IH, Mohan RKA. Lipoprotein (a) in clinical practice. J Pak Med Assoc. 2014;64 (4):447–450. 35. Kamstrup PR, Tybjaerg-Hansen A, Steffensen R, Nordestgaard BG. Genetically elevated lipoprotein (a) and increased risk of myocardial infarction. J Am Med Assoc. 2009;301 (22):2331–2339. 36. Khera AV, Everett BM, Caulfield MP, Hantash FM, Wohlgemuth J, Ridker PM, Mora S. Lipoprotein (a) concentrations, rosuvastatin therapy, and residual vascular risk: an analysis from the JUPITER Trial (Justication for the Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin). Circulation. 2014;129(6):635-642. 37. Koschinsky M, Marcovina SM. Lipoprotin (a). In: C. Ballantyne, ed. Clinical lipidology: a companion to Braunwald’s heart disease. Philadelphia: Saunders Elsevier, 2009. P. 130-143. 38. L. Wallentin, C. Held, P. W. Armstrong [et al.] // J. Am. Heart Assoc. – 2016. – Vol. 5, № 6. – Pii: e003407. – DOI: 10.1161/JAHA.116.003407. 39. Leander K., Malarstig A., Van’t Hooft F. M., Hyde C., Hellenius M. L., Troutt J. S., Konrad R. J., Ohrvik J., Hamsten A., de Faire U. Circulation. 2016, vol. 133 (13),pp. 1230–1239. 40. Li S., Guo Y. L., Xu R. X., Zhang Y., Zhu C. G., Sun J., Qing P., Wu N. Q., Jiang L. X., Li J. J. Atherosclerosis. 2014, vol. 234 (2), pp. 441‒445. 41. Lipid‐related markers and cardiovascular disease prediction /E. Angelantonio Di, P. Gao, L. Pennells [et al.] // JAMA. – 2012. – Vol. 307, № 23. – P. 2499–2506. – DOI: 10.1001/jama.2012.6571. 42. Lipoprotein associated phospholipase A2 concentration predicts total and cardiovascular mortality independently of established risk factors (The Ludwigshafen Risk and Cardiovascular Health Study / M. E. Kleber, R. L. Wolfert De, G. D. Moissl [et al.]. – Text : electronic // Clin. Lab. – 2011. – Vol. 57, № 9. – P. 659–667. – URL: https://www.ncbi.nlm.nih.gov/pubmed/22029180 (date of the application: 04.10.2019). 43. Lipoprotein-associated phospholipase A (2) and risk of coronary disease, stroke, and mortality: collaborative analysis of 32 prospective studies / Lp-PLA2 Studies Collaboration [et al.] // Lancet. – 2010. – Vol. 375. – P. 1536–44. – DOI: 10.1016/S0140-6736(10)60319-4. 44. Lipoprotein-associated phospholipase A2 and risk of incident peripheral arterial disease in older adults: The Cardiovascular Health Study / P. K. Garg,M. Arnold, K. D. Stukovsky [et al.] // Arterioscler. Thromb. Vasc. Biol. – 2016. – Vol. 36, № 4. – P. 750–756. – DOI: 10.1161/ATVBAHA.115.306647. 45. Lipoprotein-associated phospholipase A2 and risk of incident peripheral arterial disease in a multi-ethnic cohort: The Multi-Ethnic Study of Atherosclerosis / P. K. Garg, F. L. Norby, L. M. Polfus [et al.] // Vasc. Med. – 2017. – Vol. 22, № 1. – P. 5–12. – DOI: 10.1177/1358863X16671424. 46. Lipoprotein-associated phospholipase A2 and risk of incident peripheral arterial disease: Findings from The Atherosclerosis Risk in Communities study (ARIC)/ P. K. Garg, A. M. Arnold, K. D. Stukovsky [et al.] // Atherosclerosis. – 2018. – Vol. 268. – P. 12–18. DOI: 10.1016/j.atherosclerosis.2017.11.007. 47. Lipoprotein-associated phospholipase A2 is highly expressed in macrophages of coronary lesions prone to rupture / F. D. Kolodgie, A. P. Burke, A. Taye [et al.] // Circulation. – 2004. – Vol. 110, № 3. – P. 246–247. – DOI: 10.1161/01.ATV.0000244681.72738.bc 48. Loscalzo J, Weinfeld M, Fless GM, Scanu AM. Lipoprotein (a), 捯brin binding, and plasminogen activation. Arteriosclerosis. 1990;10 (2):240–245. 49. Lp-PLA2 activity and mass and CRP are associated with incident symptomatic peripheral arterial disease / S. Fatemi, A. Gottsäter, M. Zarrouk [et al.] // Sci. Rep. – 2019. – Vol. 9, № 1. – P. 5609. – DOI: 10.1038/s41598-019-42154-5. 50. Mallat, Z. Lipoprotein‐associated and secreted phospholipases A (2) in cardiovascular disease: roles as biological effectors and biomarkers / Z. Mallat, G. Lambeau, A. Tedgui // Circulation. – 2010. – Vol. 122, № 21. – P. 2183–2200. – DOI: 10.1161/Circulationaha.110.936393. 51. Marcovina SM, Koschinsky ML, Albers JJ, Skarlatos S. Report of the National Heart, Lung, and Blood Institute Workshop on lipoprotein (a) and cardiovascular disease: recent advances and future directions. Clinical Chemistry. 2003;49 (11):1785–1796. 52. Y, Himeno H, Yakuwa H, Usui T. Serum lipoprotein (a) level and clinical coronary stenosis progression in patients with myocardial infarction: re-revascularization rate is high in patients with high-Lp (a). Circ J. 2006;70(2):156–162. 53. Murase T, Okubo M, Amemiya-Kudo M. Impact of markedly elevated serum lipoprotein (a) levels on the risk of coronary heart disease. Metabolism. 2007;56(9):1187–1191. 54. National Association of Statutory Health Insurance Physicians (KBV Qualitдtsbericht). Quality report. 2013;47–48 [In German]. 55. Nichols M., Townsend N., Scarborough P., Rayner M. Cardiovascular disease in Europe 2014: epidemiological update. // Eur Heart J. – 2014. – Vol.35. – P.2950-9. 56. Park S. W., Moon Y. A., Horton The Journal of Biological Chemistry. 2004, vol. 279 (48), pp. 50630‒50638. Maxwell K. N., Fisher E. A., Breslow J. L. Proc. Natl. Acad. Sci USA. 2005, vol. 102 (6), pp. 2069‒2074. 57. Pathologic assessment of the vulnerable human coronary plaque / F. D. Kolodgie, R. Virmani, A. P. Burke [et al.] // Heart. – 2004. – Vol. 90, № 12. – P. 1385–1391. – DOI: 10.1136/hrt.2004.041798. 58. Relationship of lipoprotein‐associated phospholipase A(2) mass and activity with incident vascular events among primary prevention patients allocated to placebo or to statin therapy: an analysis from the JUPITER trial / P. M. Ridker, J. G. MacFadyen, R. L. Wolfert, W. Koenig // Clin. Chem. – 2012. – Vol. 58, № 5. – P. 877–886. – DOI: 10.1373/clinchem.2011.180281. 59. Roubtsova A., Munconda M. N., Awan Z., Marcinkiewicz J., Chamberland A., Lazure C., Cianflone K., Seidah N. G., Prat A. Arteriosclerosis, Thrombosis, and Vascular Biology. 2011, vol. 31 (4), pp. 785‒791. 60. Seidah N.G., Benjannet S., Wickham L. et al. The secretory proprotein convertase neural apoptosis-regulated convertase 1 (NARC-1): liver regeneration and neuronal differentiation // Proc. Natl. Acad. Sci. USA. 2003. Vol. 100. P. 928–933. 61. Sudhir, K. Clinical review:Lipoprotein-associated phospholipase A2, a novel inflammatory biomarker and independent risk predictor for cardiovascular disease K. Sudhir // J. Clin. Endocrinol. Metab. – 2005. – Vol. 90, № 5. – P. 3100–3105. – DOI: 10.1210/jc.2004-2027. 62. Toth S., Fedacko J., Pekarova T., Hertelyova Z., Katz M., Mughees A., Kuzma J., Stefanic P., Kopolovets I., Pella D. Cardiol. Ther. 2017, vol. 6 (2), pp. 281‒289. 63. Tsimikas S, Hall JL. Lipoprotein (a) as a potential causal genetic risk factor of cardiovascular disease: a rationale for increased efforts to understand its pathophysiology and develop targeted therapies. J Am Coll Cardiol. 2012;60(8):716–721. 64. Virani SS, Brautbar A, Davis BC, Nambi V, Hoogeveen RC, Sharrett AR et al. Associations between lipoprotein (a) levels and cardiovascular outcomes in black and white subjects: the Atherosclerosis Risk in Communities (ARIC) Study.Circulation.12;125(2):241–249 65. Walley K. R., Francis G. A., Opal S. M., Stein E. A., Russell J. A., Boyd J. H. Am. J. Respir. Crit. Care Med. 2015, vol. 191 (11), pp. 1275‒1286. 66. Walley K. R., Thain K. R., Russell J. A., Reilly M. P., Meyer N. J., Ferguson J. F., Christie J. D., Nakada T. A., Fjell C. D., Thair S. A., Cirstea M. S., Boyd J. H. SciTransl. Med. 2014, vol. 6 (258), pp. 258ra143. 67. Walley K. R. Curr. Opin. Crit. Care. 2016, vol. 22 (5), pp. 464‒469. 68. Zaid A., Roubtsova A., Essalmani R. et al. Proprotein convertase subtilisin ⁄ kexin type 9 (PCSK9): hepatocyte-specific low-density lipoprotein receptor degradation and critical role in mouse liver regeneration // Hepatology. 2008. Vol. 48. P. 646–654. 69. Zairis MN, Ambrose JA, Manousakis SJ, Stefanidis AS, Papadaki OA, Bilianou HI et al. The impact of plasma levels of C-reactive protein, lipoprotein (a) and homocysteine on the long-term prognosis after successful coronary stenting: The Global Evaluation of New Events and Restenosis After Stent Implantation Study. J Am Coll Cardiol. 2002;40(8):1375–1382. 70. Z. Li, W. Ren, X. Han [et al.] ω3-polyunsaturated fatty acids suppress lipoprotein-associated phospholipase A2 expression in macrophages and animal models // Mol. Nutr. Food Res. – 2015. – Vol. 59, № 9. – P. 1771–1779. – DOI: 10.1002/mnfr.201500022.

Share

COinS
 
 

To view the content in your browser, please download Adobe Reader or, alternately,
you may Download the file to your hard drive.

NOTE: The latest versions of Adobe Reader do not support viewing PDF files within Firefox on Mac OS and if you are using a modern (Intel) Mac, there is no official plugin for viewing PDF files within the browser window.